The pharma manufacturer Curia plans to spend $40 million at facilities in upstate New York.
The Albany-based company, formerly called AMRI, plans to invest in its three facilities in Rensselaer, Albany and Buffalo, according to the latest board agenda for NY CREATES.
Curia leases 47,000 square feet on the seventh floor of the Conventus Building in Buffalo. An entity that is now an arm of NY CREATES purchase that floor of the building in 2015.
Curia is focusing on cancer drugs and enabling the development and the manufacturing of treatments targeting Covid-19, the board agenda said.
Curia is a contract research, development and manufacturing organization that serves the pharmaceutical and biopharmaceutical industries. The company says its services are meant to help clients move ideas to commercialization.
Curia in August said that it would be investing $35 million to build out manufacturing operations at its Rensselaer facility, which it says will enhance its ability to partner with customers and complete small and large orders.
The Rensselaer expansion will include new equipment that more than doubles the output capacity. It will allow the site to offer a variety of new products and enable Curia to meet growing demand for high-potency active ingredients used in medications. Curia said the expansion will include efforts toward energy and environmental sustainability.
“Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs. The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs,” said John Ratliff, Curia chairman and CEO, in a statement.
Curia said the expansion will create new technical jobs in Rensselaer. It’s expected to be completed within 18 months.
Curia did not respond to a request for further comment.
Curia in July announced plans to acquire California-based LakePharma Inc., which closed in September, and California-based Integrity Bio Inc. Bloomberg reported that the deals were collectively worth more than $500 million, including debt.
Curia said in August that it now has 3,400 employees at 23 locations in the U.S., Europe and Asia.
Curia is backed by private equity firms The Carlyle Group of Washington, D.C., and GTCR LLC. The firms purchased the company in 2017 for $21.75 a share, approximately $920 million.
Curia said its rebrand from AMRI, announced in July, better positions the company for continued growth in the life sciences industry.
© 2021 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement (updated 1/1/21) and Privacy Policy and Cookie Statement (updated 7/20/21). The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of American City Business Journals.
Curia, formerly AMRI, plans investment in Albany, Rensselaer and Buffalo – Albany Business Review – Albany Business Review
